135 results on '"Aulakh, Sonikpreet"'
Search Results
2. Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target
3. Unraveling the immunologic vulnerabilities of diffuse hemispheric glioma, H3 G34-mutant.
4. VISTA Emerges as a Promising Target against Immune Evasion Mechanisms in Medulloblastoma.
5. Sex differences in glioblastoma response to treatment: Impact of MGMT methylation
6. Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis
7. Utilization of radiation therapy in multiple myeloma: trends and changes in practice
8. Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients
9. RTID-08. A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGO IMV-001 TARGETING IGF-1R, VS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS
10. Survival trends in glioblastoma and association with treating facility volume
11. Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients.
12. Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target
13. Feasibility of a clinically integrated rehabilitation therapist in a Neuro-Oncology clinic
14. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia
15. Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade
16. PATH-22. CLINICAL FEATURES AND MOLECULAR CHARACTERIZATION OF LEPTOMENINGEAL DISEASE IN PATIENTS WITH HIGH GRADE GLIOMA
17. S2429 A Rare Case of Esophageal Adenocarcinoma Presenting as an Isolated Brain Lesion 6 Years After Treatment
18. Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?
19. The Roadmap to Pituitary in COVID-19 Crisis
20. Abstract 2991: Survival reliability of Glioblastoma on CD38
21. Abstract 356: Pre-clinical investigations utilizing Bcl2 inhibitors in glioblastoma
22. Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target.
23. Detection of high-grade glioma clusters: Spatial case-control study using EMR data from 2010-2021.
24. Biological and prognostic relevance of epigenetic regulatory genes in high-grade gliomas (HGGs).
25. Chapter 9 - Management of Primary Central Nervous System Lymphoma
26. Abstract PO-104: Disparity in race and age reporting in landmark cancer clinical trials: Underrepresentation of the traditionally underserved U.S. population
27. Xanthomatous meningioma, a rare histological variant: Case report
28. Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting
29. BIOM-17. DIFFERENCES IN THE IMMUNE MICROENVIRONMENT OF GLIOMAS HARBORING IDH2 VERSUS IDH1 MUTATIONS
30. Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases
31. Targeting drug resistance in glioblastoma (Review).
32. Radiosurgery for Trigeminal Neuralgia Secondary to Dolichoectatic Vessels: Case Series and Review of Literature
33. Impact of COVID-19 Pandemic on Cancer Screening in the United States
34. Is Glutamine Responsible for the Radiosensitivity of Subthalamic Nucleus?
35. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses
36. Therapeutic targeting of CD38 enhances temozolomide activity in glioblastoma cells and modulates their tumor microenvironment by eliciting an enhanced CD8+ T cell response
37. Contributors
38. Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells
39. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia
40. CD38hi B-regulatory (B-reg) cells maintain pathological immune tolerance in chronic lymphocytic leukemia (CLL)/B cell diseases: Potential therapeutic considerations
41. Lenolidamide and IL-15 enhance natural killer cell-mediated immunity and augments the anti-tumor effect of an anti-CD30/CD16A bispecific antibody against Hodgkin’s lymphoma B-cells
42. Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with Richter Syndrome: A Systematic Review and Meta-Analysis
43. Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia
44. Disparity in Clinical Trial Opportunities for Patients with B-Cell Malignancies in the United States
45. Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome
46. Timeliness of Initial Therapy in Multiple Myeloma (MM): Trends and Factors Influencing Patient Care
47. Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia(CLL)
48. HOUT-23. ASSOCIATION BETWEEN TREATMENT FACILITY VOLUME AND MORTALITY IN PATIENTS WITH GLIOBLASTOMA (GBM): A LARGE NATIONAL ANALYSIS
49. EXTH-06. CD38-TARGETED THERAPY IN GLIOBLASTOMA
50. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.